X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (459) 459
Publication (49) 49
Book Review (19) 19
Book / eBook (2) 2
Patent (2) 2
Conference Proceeding (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (244) 244
index medicus (202) 202
oncology (184) 184
male (151) 151
female (142) 142
middle aged (136) 136
carcinoma, renal cell - drug therapy (129) 129
kidney neoplasms - drug therapy (126) 126
cancer (115) 115
aged (111) 111
adult (92) 92
kidney neoplasms - pathology (91) 91
sunitinib (87) 87
carcinoma, renal cell (82) 82
renal cell carcinoma (81) 81
interferon-alpha (73) 73
antineoplastic agents - therapeutic use (71) 71
disease-free survival (65) 65
survival (65) 65
carcinoma, renal cell - pathology (63) 63
treatment outcome (63) 63
care and treatment (62) 62
metastasis (61) 61
sorafenib (61) 61
bevacizumab (53) 53
carcinoma, renal cell - secondary (52) 52
aged, 80 and over (51) 51
urology & nephrology (50) 50
prognosis (47) 47
kidney neoplasms - mortality (45) 45
neoplasm metastasis (45) 45
therapy (45) 45
carcinoma, renal cell - mortality (44) 44
everolimus (43) 43
hematology, oncology and palliative medicine (41) 41
kidney cancer (40) 40
niacinamide - analogs & derivatives (40) 40
targeted therapy (39) 39
nephrectomy (38) 38
urology (38) 38
immunotherapy (36) 36
analysis (35) 35
antineoplastic agents - adverse effects (35) 35
double-blind (34) 34
antineoplastic combined chemotherapy protocols - therapeutic use (33) 33
drug therapy (33) 33
life sciences (33) 33
tumors (32) 32
vascular endothelial growth factor (32) 32
efficacy (31) 31
research (31) 31
antineoplastic agents (30) 30
abridged index medicus (29) 29
retrospective studies (29) 29
risk factors (29) 29
sirolimus - analogs & derivatives (29) 29
antimitotic agents (28) 28
phenylurea compounds (28) 28
trial (28) 28
carcinoma, renal cell - therapy (27) 27
clinical trials (27) 27
metastases (27) 27
clear cell-type renal cell carcinoma (26) 26
kidney neoplasms - therapy (26) 26
patients (26) 26
protein kinase inhibitors - therapeutic use (26) 26
endothelial growth-factor (25) 25
patient outcomes (25) 25
survival analysis (25) 25
kaplan-meier estimate (24) 24
medicine, general & internal (24) 24
survival rate (24) 24
angiogenesis (23) 23
animals (23) 23
antineoplastic agents - administration & dosage (23) 23
carcinoma (23) 23
carcinoma, renal cell - genetics (23) 23
adolescent (22) 22
time factors (22) 22
young adult (22) 22
angiogenesis inhibitors - therapeutic use (21) 21
chemotherapy (21) 21
kidney neoplasms - genetics (21) 21
renal-cell carcinoma (21) 21
article (20) 20
molecular targeted therapy (20) 20
prospective studies (20) 20
carcinoma, renal cell - metabolism (19) 19
expression (19) 19
follow-up studies (19) 19
health aspects (19) 19
kidney neoplasms - metabolism (19) 19
sirolimus - therapeutic use (19) 19
tyrosine kinase inhibitor (19) 19
diagnosis (18) 18
inhibitor (18) 18
kidney neoplasms - surgery (18) 18
phase-ii (18) 18
pyridines - therapeutic use (18) 18
vascular endothelial growth factor a - antagonists & inhibitors (18) 18
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 02/2017, Volume 35, Issue 6_suppl, pp. 481 - 481
481 Background: Response assessment under immune checkpoint inhibitors is a challenge that RECIST criteria may not adequately reflect. TGR takes into account... 
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2017, Volume 35, Issue 6_suppl, pp. 447 - 447
447 Background: ER models were previously developed to characterize the relationship between C exposure and efficacy endpoints in RCC pts in the phase III... 
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2016, Volume 34, Issue 15_suppl, pp. 4561 - 4561
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2017, Volume 35, Issue 6_suppl, pp. 420 - 420
420 Background: Late relapse in patients with germ cell tumors (GCT) are rare events. As there is no consensus for follow-up (FU) protocols, it is unclear if... 
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2016, Volume 34, Issue 15_suppl, pp. e16113 - e16113
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2015, Volume 33, Issue 7_suppl, pp. 488 - 488
488 Background: Temsirolimus is currently the standard of care for poor risk RCC, based on the pivotal trial. Whether everolimus could be an alternative for... 
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2015, Volume 33, Issue 7_suppl, pp. 437 - 437
437 Background: Local treatment of BM in mRCC pts comprises different approaches including thermal ablation techniques as well as radiofrequency ablation (RFA)... 
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2016, Volume 34, Issue 2_suppl, pp. 580 - 580
580 Background: Axitinib is used after failure of first line treatment for metastatic renal cell carcinoma (mRCC). A common side effect of axitinib is the... 
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2014, Volume 32, Issue 15_suppl, pp. TPS4601 - TPS4601
Journal Article
Journal of Experimental Medicine, ISSN 0022-1007, 10/2005, Volume 202, Issue 8, pp. 1075 - 1085
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2014, Volume 32, Issue 4_suppl, pp. 526 - 526
526 Background: Tyrosine kinase inhibitors including sunitinib are the most effective treatments of metastatic renal cell carcinoma (mRCC). A multi-centric... 
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2013, Volume 31, Issue 6_suppl, pp. 352 - 352
352 Background: Compared with placebo, everolimus provided significant improvement in median PFS in the RECORD-1 study of VEGFr-TKI-refractory mRCC. To... 
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2012, Volume 30, Issue 5_suppl, pp. 360 - 360
360 Background: Translocation renal cell carcinoma (RCC) is a rare subtype of kidney cancer that is characterized by translocations involving TFEB or TFE3... 
Journal Article
Oncology Reviews, ISSN 1970-5557, 12/2011, Volume 1, Issue 2, pp. 73 - 80
Temsirolimus is a novel inhibitor of mammalian target of rapamycin (mTOR), which is a central regulator of the response of tumour cells to growth and survival... 
Temsirolimus - Kidney cancer - Renal cell carcinoma - mTOR - Targeted therapy
Journal Article
Oncology Reviews, ISSN 1970-5557, 12/2011, Volume 1, Issue 2, p. 73
Temsirolimus is a novel inhibitor of mammalian target of rapamycin (mTOR), which is a central regulator of the response of tumour cells to growth and survival... 
Temsirolimus - Kidney cancer - Renal cell carcinoma - mTOR - Targeted therapy
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.